Nevertheless, given the pro-metabolic role of LRH-1 in glucose homeostasis, this potential LRH-1 agonist treatment has to contemplate also the medical and metabolic patient history in order to pay the view of the personalized healthcare of CRC. This evidence concerns the gene NR5A2 and colorectal carcinoma.